Cholinesterase inhibitors reduce aggression, wandering and paranoia in Alzheimer's disease

December 10, 2008

INDIANAPOLIS - Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer's disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dementia, according to a study that appears in the December 2008 edition of Clinical Interventions in Aging.

Investigators from the Indiana University School of Medicine, the Regenstrief Institute and Wishard Health Services reviewed nine randomized, double-blind, placebo-controlled clinical trials evaluating the effectiveness of three popular cholinesterase inhibitors in managing behavioral and psychological symptoms displayed by patients with Alzheimer's disease.

The researchers report that the trial results indicate cholinesterase inhibitors led to a statistically significant reduction in behavioral and psychological symptoms such as aggression, wandering or paranoia when using the same dosage as administered for improving cognitive impairment.

Nine out of 10 Alzheimer's disease patients display behavioral and psychological symptoms of their disease. The review of the clinical trials revealed that cholinesterase inhibitors are safe, producing no major side effects.

"There is a need for safe alternatives to the anti-psychotic drugs currently used to manage the behavioral and psychological symptoms of Alzheimer's disease. The results of the studies we analyzed are encouraging and suggestive that cholinesterase inhibitors are safe and effective alternatives. However, they are underutilized and typically prescribed for less than three months and for less than 10 percent of patients with Alzheimer's disease. Our findings might provide clinicians with useful data to justify the appropriate use of these medications," said Malaz Boustani, M.D., corresponding author of the Clinical Interventions in Aging paper. Dr. Boustani is assistant professor of medicine at the IU School of Medicine, a Regenstrief Institute research scientist, a research investigator with the IU Center for Aging Research, and chief research officer of the Indianapolis Discovery Network for Dementia.

In Alzheimer's disease there is a decrease in acetylcholine, a chemical in the brain that assists memory, thought and judgment. Cholinesterase inhibitors raise acetylcholine levels. Increased concentrations of acetylcholine in the brain leads to increased communication between nerve cells and may improve or stabilize the symptoms of Alzheimer's disease in the early and moderate stages of progression.

Noll Campbell, PharmD, a clinical pharmacy specialist in geriatric psychiatry with Wishard Health Services and corresponding author of the paper, said that, "This class of medications has already been approved by the Food and Drug Administration to manage symptoms of Alzheimer's-type dementia, although their potential benefits on behavioral symptoms are not frequently identified by many prescribers. Clinical trials of cholinesterase inhibitors have shown benefits in several domains of cognitive function as well as behavioral symptoms associated with dementia, and may improve the management of behavioral problems while reducing the use of more harmful medications that are needed to control behaviors."

Dr. Boustani noted that the vast majority of busy primary care physicians, the doctors who see the majority of patients with Alzheimer's disease, are unaware of the details of the studies analyzed in the Clinical Interventions in Aging paper and he hopes that this new paper, which reviewed the studies, will encourage them to prescribe cholinesterase inhibitors, with its benefits for both cognition and behavior symptoms to their Alzheimer's disease patients.

Indiana University

---

---

	Human Cholinesterases and Anticholinesterases by Hermona Soreq (Author), Haim Zakut (Author) Molecular biological approaches have deepened our understanding of the role that cholinesterases play in regulating the action of the neurotransmitter acetylcholine, in embryonic cell development and in tumour development. This text reviews the latest molecular studies of cholinesterase expression, structure and function. "Human Cholinesterases and Anticholinesterases" is conveniently divided into three parts, each of which presents different points of view on human cholinesterase research. The first part discusses the biochemical and biological backgound on human CHEs, taking into consideration our recently acquired molecular know-how; the second displays an updated report of the molecular characterization of the human cholinesterase genes and their multi-leveled regulation; and the...
	Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Conference Proceedings Series) by Jean Massoulï¿1/2e (Editor), Eric Barnard (Editor), Arnaud Chatonnet (Editor), Francis Bacou (Editor), Bhupendra P. Doctor (Editor), Daniel M. Quinn (Editor) Presenting the proceedings of the Third International Meeting on Cholinesterases, this volume provides a wealth of new information on current cholinesterase research and explores a number of avenues for future research. Important advances resulting from new concepts and methodologies such as monoclonal antibodies and molecular genetics, are covered. Among the topics covered in its 49 full papers and 140 poster papers are polymorphism and structure, cellular biology, gene structure and expression, agents, and noncholinergic roles of cholinesterases.
	Butyrylcholinesterase: Its Function and Inhibitors by Ezio Giacobini (Editor) Two types of cholinesterases (ChEs) are found in the mammalian brain: acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). They are products of two different genes and exhibit different localizations and kinetic properties. Until recently, the function of BuChE and its role in the regulation of acetylcholine levels in the central nervous system have been largely unknown. There is now evidence that BuChE plays a vital role in the brain cholinergic system, and that it may have a key role in the development of Alzheimer's disease. Butyrylcholinesterase: Its Function and Inhibitors is for neurologists, psychiatrists, geriatricians and neuroscientists who want a full profile of BuChE.
	A review of modern literature on the chemistry and toxicology of organophosphorus inhibitors of cholinesterases, by N. A. Smirnov, V. V. Loshadkin (Author)
	Cholinesterase inhibitors underused.(Geriatrics): An article from: Internal Medicine News by Sally Koch Kubetin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on December 1, 2004. The length of the article is 479 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Cholinesterase inhibitors underused.(Geriatrics) Author: Sally Koch Kubetin Publication: Internal Medicine News (Magazine/Journal) Date: December 1, 2004 Publisher: International Medical News Group Volume: 37 Issue: 23 Page: 16(1) Distributed by Thomson...
	Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. (Review).: An article ... Journal of Phytotherapy & Phytopharmacology by Volker Schulz (Author) This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Urban & Fischer Verlag on May 1, 2003. The length of the article is 3950 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. (Review). Author: Volker Schulz Publication: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Refereed) Date: May 1, 2003 Publisher: Urban & Fischer Verlag Volume: 10 ...
	Start cholinesterase inhibitor immediately after Alzheimer's Dx. (Improves Cognitive Function).: An article from: Clinical Psychiatry News by Sally Koch Kubetin (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on June 1, 2003. The length of the article is 486 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Start cholinesterase inhibitor immediately after Alzheimer's Dx. (Improves Cognitive Function). Author: Sally Koch Kubetin Publication: Clinical Psychiatry News (Magazine/Journal) Date: June 1, 2003 Publisher: International Medical News Group Volume: 31 Issue: 6 Page: 24(1) Distributed by Thomson...
	Cholinesterase inhibitors: the earlier, the better. (Mild to Moderate Dementia).(dementia treatment): An article from: Internal Medicine News by Miriam E. Tucker (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2002. The length of the article is 765 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Cholinesterase inhibitors: the earlier, the better. (Mild to Moderate Dementia).(dementia treatment) Author: Miriam E. Tucker Publication: Internal Medicine News (Magazine/Journal) Date: October 1, 2002 Publisher: International Medical News Group Volume: 35 Issue: 19 Page: 28(1) Distributed by Thomson...
	Cholinesterase inhibitors may improve behavior in Alzheimer. (Less Agitation, Anxiety, Irritability).(Brief Article): An article from: Family Practice News by Carl Sherman (Author) This digital document is an article from Family Practice News, published by International Medical News Group on May 15, 2002. The length of the article is 452 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Cholinesterase inhibitors may improve behavior in Alzheimer. (Less Agitation, Anxiety, Irritability).(Brief Article) Author: Carl Sherman Publication: Family Practice News (Magazine/Journal) Date: May 15, 2002 Publisher: International Medical News Group Volume: 32 Issue: 10 Page: 16(1) Article Type: Brief Article Distributed by Thomson...
	Cholinesterase inhibitors seem to limit behavioral symptoms in Alzheimer's. (Limited Data).: An article from: Internal Medicine News by Carl Sherman (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on April 15, 2002. The length of the article is 436 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Cholinesterase inhibitors seem to limit behavioral symptoms in Alzheimer's. (Limited Data). Author: Carl Sherman Publication: Internal Medicine News (Magazine/Journal) Date: April 15, 2002 Publisher: International Medical News Group Volume: 35 Issue: 8 Page: 18(1) Distributed by Thomson...